Recent 8-K filings for IVF

• June 22, 2026, 9:05 AM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  INVO Fertility Q1 revenue up 23% to $2.0M; net loss widens on warrant charge, balance sheet strengthened

  Revenue $2.02M (+23% YoY); clinic revenue $1.98M (+22%) driven by organic growth and Family Beginnings acquisition.

• June 2, 2026, 8:40 AM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

  Revenue $6,841,250, up 5% from $6,532,000; consolidated clinic revenue up 4% to $6.72M.

• June 2, 2026, 8:30 AM ET other material materiality 0.75 negative item 4.02item 9.01 ◈ Auditor Changes

  INVO Fertility restates 2025 Q1-Q3 financials; non-reliance due to accounting errors

  Non-reliance on unaudited 10-Qs for Q1-Q3 2025 due to errors in derivative, debt extinguishment, and preferred stock classification.

• April 29, 2026, 7:59 PM ET regulatory materiality 0.60 negative item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices

  INVO Fertility receives Nasdaq deficiency notice for late 10-K filing

  Received Nasdaq notice on April 23, 2026, for failing to file 2025 Form 10-K by April 15, 2026.

• March 31, 2026, 7:59 PM ET other material materiality 0.60 neutral item 5.03item 8.01item 9.01 ◈ Governance Changes

  INVO Fertility to effect 1-for-5 reverse stock split effective March 27, 2026

  Reverse split ratio: 1-for-5; effective 12:01 a.m. ET on March 27, 2026.

• February 24, 2026, 6:59 PM ET M&A materiality 0.75 positive item 1.01item 2.01item 5.03item 3.02item 8.01item 9.01 ◈ Equity Issuances◈ Governance Changes◈ M&A Transactions

  INVO Fertility closes acquisition of Family Beginnings clinic for $760K (cash + preferred stock)

  Total purchase price $760K: $360K cash (net $210K after $150K holdback) plus 400 shares of Series D Preferred ($400K).

• January 30, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Equity Issuances◈ Material Agreements

  INVO Fertility raises $7.5M via warrant exercise; issues new warrants for 9.5M shares

  Holder exercises 4,733,728 existing warrants at reduced $1.59 price, gross proceeds ~$7.5M.

• January 26, 2026, 6:59 PM ET other material materiality 0.85 neutral item 5.03item 5.07item 9.01 ◈ Governance Changes

  INVO Fertility shareholders approve increase in authorized shares from 6.25M to 250M and warrant issuance

  Authorized common shares increased from 6,250,000 to 250,000,000 via Certificate of Amendment filed Jan 22.

• December 17, 2025, 6:59 PM ET M&A materiality 0.65 positive item 1.01item 8.01item 9.01 ◈ Material Agreements

  INVO Fertility signs definitive agreement to acquire Indiana fertility clinic Family Beginnings for $750K

  Total purchase price $750K: $350K cash (less $150K holdback) plus $400K in Series D convertible preferred stock.

• December 5, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Equity Issuances ×3◈ Material Agreements ×3

  INVO Fertility raises $4.0M in private placement of stock and warrants

  Gross proceeds ~$4.0M from 2,366,864 shares/pre-funded warrants plus 4,733,728 common warrants at $1.69 combined.

• October 3, 2025, 7:59 PM ET litigation materiality 0.80 negative item 1.01item 3.02item 9.01 ◈ Equity Issuances

  INVO Fertility settles litigation with Dr. Pritts for $6.01M; issues preferred shares

  Settlement requires Wood Violet to pay Dr. Pritts $6,010,000 in installments through Dec 2026, with $1M already paid.

• September 26, 2025, 7:59 PM ET debt materiality 0.65 negative item 1.01item 9.01

  INVO Fertility restructures Decathlon loan; payment up $20k/mo, interest multiples raised

  Monthly loan payment increased by $20,000 beginning August 2025.

• August 22, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 3.02item 3.03item 9.01

  INVO Fertility exchanges debenture with Five Narrow Lane, reduces principal to $1.75M and issues preferred stock

  Principal reduced to $1,751,343.75 via $1,300,000 exchange for 325 Series C-2 Preferred shares with $1.3M stated value.

• August 15, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  INVO Fertility Q2 2025 revenue up 1% to record $1.86M, net loss widens to $3.2M

  Q2 2025 revenue $1,863,654 (record), up 1% YoY; clinic revenue $1,832,094 up 1%.

• July 23, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02item 1.01item 5.07

  INVO Fertility authorized shares increased to 50M from 1.39M; issues $200k preferred

  Shareholders approved increasing authorized common shares from 1,388,888 to 50,000,000; vote: 643,612 for, 219,764 against, 5,008 abstain.

• July 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.03item 8.01item 9.01 ◈ Governance Changes

  INVO Fertility 1-for-3 reverse stock split effective July 21, 2025 to meet Nasdaq bid price rule

  Reverse split at 1:3 effective pre-market July 21, 2025; new CUSIP 44984F708.

• July 1, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 3.02item 5.03item 9.01 ◈ Governance Changes

  INVO Fertility amends SPA, exchanges $1.8M debenture for preferred shares, issues inducement shares

  Amendment to SPA allows Holder to exchange up to $10M of C-2 Preferred for Debenture, minimum $200k.

• June 6, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 2.01item 9.01 ◈ M&A Transactions

  INVO Fertility divests majority holdings in NTI, retains preferred stake and note

  Effective June 2, 2025, INVO redeemed all Series C-1 Preferred for 3,227,813 shares of NTI Class A Common, ceasing to hold NTI common.

• May 30, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 3.03item 5.02item 5.03item 8.01 ◈ executive_change

  INVO restructures NTI holdings with $4.8M note and preferred stock amendments

  Exchanged 801,196 NTI shares (19.9% stake) for 6,300 NTI Series A Preferred shares, $1,000 stated value each.

• May 21, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  INVO Fertility Q1 2025 revenue up 4% but net loss widens to $17.4M on $14.6M impairment

  Revenue $1.64M, +4% YoY; clinic revenue from consolidated centers +5% to $1.62M.

• April 30, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  INVO Fertility reports 116% revenue growth to $6.5M in FY2024; adjusted EBITDA improves to $(2.2)M

  Q4 2024 revenue $1.69M (+22% YoY); full-year revenue $6.53M (+116% YoY).

• April 30, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02

  INVO Fertility induces exercise of $8.40 warrants at $1.61, receives ~$750k gross proceeds

  Holder exercised 465,840 existing warrants at reduced exercise price of $1.61 per share.

• April 18, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01item 5.03item 9.01 ◈ Listing & Compliance Notices◈ Governance Changes

  INVO Fertility (fka NAYA) receives Nasdaq delisting notice for late 10-K; changes name to INVO Fertility

  Received Nasdaq letter on April 16, 2025 for failure to file 2024 10-K on time; 60 days to submit compliance plan.

• March 31, 2025, 7:59 PM ET other material materiality 0.65 positive item 3.01item 9.01 ◈ Listing & Compliance Notices

  NAYA regains Nasdaq compliance after reverse split; delisting averted

  Received delisting determination on Mar 25, 2025 for failing to meet $1.00 bid price rule.

• March 24, 2025, 7:59 PM ET other material materiality 0.75 negative item 5.03item 8.01item 9.01 ◈ Governance Changes

  NAYA Biosciences executes 1-for-12 reverse stock split to regain Nasdaq compliance

  Reverse split effective 12:01 a.m. ET on March 18, 2025; stock trades under same symbol 'NAYA'.

• January 16, 2025, 6:59 PM ET other material materiality 0.80 neutral item 1.01item 2.04item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices ×2

  NAYA Biosciences Prices $9.5M Public Offering and Receives Nasdaq Notice for Missing Annual Meeting

  NAYA Biosciences closed public offering of 13,615,171 units at $0.70 per unit, raising approximately $9.5 million in gross proceeds.

• December 12, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 1.01item 5.03item 9.01

  NAYA Biosciences completes merger with Legacy NAYA; stock and debt exchange detailed

  Each Legacy NAYA share exchanged for 118,148 NAYA common shares and 30,375 Series C-1 Preferred shares (convertible only after stockholder approval).

• October 15, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 1.01item 5.03item 2.01item 3.02item 5.02item 8.01item 9.01 ◈ executive_change ×3◈ M&A Transactions ×2◈ Governance Changes

  INVO Bioscience completes acquisition of NAYA, changes name to NAYA Biosciences

  NAYA stockholders receive 118,148 INVO common shares and 30,375 Series C-1 Preferred per share.

• October 1, 2024, 7:59 PM ET debt materiality 0.70 negative item 1.01item 2.03item 9.01

  INVO Bioscience enters $265k cash advance; senior lender imposes equity raise condition to avoid interest hike

  Cedar Advance LLC purchased $384,250 of future sales for gross $265,000; net proceeds $251,750.

• September 20, 2024, 7:59 PM ET other material materiality 0.60 negative item 3.01item 4.02item 9.01

  INVO Bioscience receives Nasdaq bid-price deficiency notice; restates lease accounting for 2021–2024 periods

  Nasdaq notified INVO on Sep 18, 2024, that bid price was below $1 for 34 consecutive days; 180-day cure to May 17, 2025.

• September 18, 2024, 7:59 PM ET M&A materiality 0.80 neutral item 1.01item 3.02item 9.01

  INVO Bioscience amends merger with NAYA; extends deadline to Oct 14, revised consideration

  NAYA purchased 27,500 Series A preferred shares for $137,500 on Sept 16, 2024 per Securities Purchase Agreement.

• August 14, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  INVO Bioscience Q2 2024 revenue surged 481% to $1.84M; adjusted EBITDA improved by $1.1M to $(0.5)M

  Revenue $1,836,597, up 481% YoY ($315,902); clinic revenue up 611% to $1,807,921.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

5 positive 11 negative 34 neutral

source · IVF on sec.gov